Single therapeutic vaccine has potential to fight multiple conditions

A translational team of experts in Europe say they have identified a protein which is produced naturally in the human body and can be used as a therapeutic vaccine capable of fighting a range of inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and allergic asthma.

"The implications of the findings are large as they shed light on an important way that the body combats inflammation and autoimmunity," says Shohreh Issazadeh-Navikas, the principal investigator. "Moreover, they establish a therapeutic approach for using the newly discovered protein as a treatment for multiple conditions." Issazadeh-Navikas is one of a group of investigators from Denmark, Germany and Sweden who joined forces to pursue the vaccine research, which was published in the Journal of Clinical Investigation.

The vaccine they created spurs NKT cells in the immune system, a particular type of T cell which can quell autoimmune diseases and can also play a role fighting Alzheimer's, Parkinson's, RA, AA, MS, type II diabetes and cancers.

"Our data offer a novel perspective on the physiological role of these cells in maintenance of tissue homeostasis and reduction of inflammation," said the professor.

- here's the release

Related Articles:
Vaccine cure for RA heads to human trial  

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.